637. Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment
Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, et al.
The IPSS-M risk score can be described as continuous, interpretable, and reproducible. It integrates information from 38 gene mutations. This leads to improved discrimination compared to the IPSS-R score. In addition, the IPSS-M risk score restratifies almost half of the MDS patients.
Marie Sebert, Thomas Cluzeau, Odile Beyne Rauzy, et al.
Ivosidenib achieved a significant response in MDS patients, with 91 percent particularly high in treatment-naive MDS patients at higher risk and IDH1 mutations (cohort B). Ivosidenib was well tolerated in all cohorts. Results of the molecular monitoring of IDH1 mutations will be presented in the oral session.
Lionel Ades, Sophie Dimicoli-Salazar, Marie Sebert, et al.
Lisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
See abstract for more info.
Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, et al.
In evaluable patients with MDS with a low / int risk, lenalidomide plus eltrombopag demonstrate an ORR of just under 41 percent and with a sustained response. The security profile is acceptable. See more info in the abstract.
Guillermo Garcia-Manero, James K McCloskey, Elizabeth A. Griffiths, et al.
An oral fixed-dose combination of decitabine/cedazuridine showed an equivalent PK exposure of 20 mg / m2 IV DEC in MDS patients and led to mlFS and mOS of more than 32 months. For MDS patients with lower risk and indicated treatment, the active ingredient was generally well tolerated after prolonged treatment.